The American Journal of Surgery
Volume 198, Issue 3 , Pages 354-358 , September 2009

The necessity of chemotherapy in T3N0M0 colon cancer without risk factors

Received 10 July 2008 ,Revised 9 September 2008

References 

  1. Ota D, Nelson H. The surgeon and adjuvant therapy for stage II colon cancer. Ann Surg Oncol. 2007;14:272–273
  2. Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10:65–71
  3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425
  4. Sakamoto J, Ohashi Y, Hamada C, et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004;22:484–492
  5. Glimelius B, Dahl O, Cedermark B, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol. 2005;44:904–912
  6. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with Stage II colon cancer. J Clin Oncol. 2002;20:3999–4005
  7. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17:1349–1355
  8. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site group. J Clin Oncol. 2004;22:3395–3407
  9. Sakamoto J, Hamada C, Kodaira S, et al. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data metal-analysis of randomized trials. Jpn J Clin Oncol. 1999;29:78–86
  10. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol 100-06. J Clin Oncol. 2006;24:2059–2064
  11. Kim DJ, Kim TI, Suh JH, et al. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei Med J. 2003;44:665–675
  12. Green FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed.. Chicago, IL: American Joint Committee on Cancer; 2002;
  13. Morris M, Platell C, McCaul K, et al. Survival rates for Stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis. 2007;22:887–895
  14. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19:157–163
  15. Andre T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol. 2006;13:887–898
  16. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735–1743
  17. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer (International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators). J Clin Oncol. 1999;17:1356–1363
  18. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001;28:20–24
  19. Petersen VC, Baxter KJ, Love SB, et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut. 2002;51:65–69
  20. Morris E, Maughan NJ, Forman D, et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer?—The need for high quality pathology. Gut. 2007;
  21. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912–2919
  22. Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219–225
  23. Burdy G, Panis Y, Alves A, et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001;44:1682–1688
  24. Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg. 2002;235:458–463
  25. Wong JH, Severino R, Honnebier MB, et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol. 1999;17:2896–2900
  26. Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer. 2005;41:272–279
  27. Colon cancer (National Comprehensive Cancer Network (NCCN)) V 1.2008 2007.
  28. Alexander D, Jhala N, Chatla C, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer. 2005;103:2163–2170

PII: S0002-9610(08)00899-4

doi: 10.1016/j.amjsurg.2008.09.027

The American Journal of Surgery
Volume 198, Issue 3 , Pages 354-358 , September 2009

Article Tools

* Image Usage & Resolution